Who We Are
Cyclacel is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis biology. Our strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates that address oncology and hematology indications.
About Cyclin-Dependent Kinases and Fadraciclib
Cyclin-dependent kinases (CDKs) are critical for cell cycle control and transcriptional regulation. Dysregulated CDKs have been linked to the cancer hallmarks of uncontrolled proliferation and increased cancer cell survival. Our leading drug candidate, fadraciclib, is a highly selective potent, orally available, next generation inhibitor of CDK2 and CDK9. By inhibiting CDK2 and CDK9 fadraciclib has been shown to induce cancer cell death. Further information on fadraciclib.
